CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gattei, V.
Right arrow Articles by Pinto, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gattei, V.
Right arrow Articles by Pinto, A.

Cell Growth & Differentiation, Vol 7, Issue 6 753-763, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor

V Gattei, D Aldinucci, JM Quinn, M Degan, M Cozzi, V Perin, AD Iuliis, S Juzbasic, S Improta, NA Athanasou, LK Ashman and A Pinto
Unita Operativa Leucemie e Trapianto di Midollo, I.N.R.C.C.S., Aviano, Italy.

Bone remodeling requires cooperation between osteoclasts and other specialized or accessory bone cell populations by mechanisms that have not been completely elucidated. Here we describe the expression and functional role of the proto-oncogene c-kit and of its specific ligand stem cell factor (SCF) on human osteoclasts, osteoblasts, and stromal cells derived from different sources. Our results indicate that primary osteoclasts in imprints of metaphyseal bone and giant cell tumors (GCTs) of bone, as well as a bone marrow-derived preosteoclast cell line of human origin (FLG 29.1), expressed immunodetectable c-kit protein. In contrast, tissue osteoclasts did not react with anti-SCF antibodies, and barely detectable levels of SCF mRNA and protein were found in FLG 29.1 cells. Conversely, a strong expression of membrane bound-SCF was found in primary cultured bone marrow stromal cells, in a stromal cell line (C433) derived from the mononuclear component of GCT of bone, and in a human cell line with osteoblast features (Saos-2). FLG 29.1 preosteoclast cells displayed about 29,000 binding sites/cell of a single class of high affinity c-kit receptors (Kd 6.12 x 10(-10) mol/L) with a molecular weight of about 140 kDa, along with a structurally normal c-kit mRNA. Proliferation of FLG 29.1 preosteoclast cells was stimulated by exogenous SCF, indicating that c-kit was capable of transducing growth signals. Finally, in vitro adhesion of FLG 29.1 cells to primary bone marrow stromal cells, GCT-derived stromal cells (C433), and Saos-2 osteoblast cells was significantly inhibited by an excess of soluble SCF or by monoclonal antibodies recognizing SCF binding sites on the c-kit receptor. These results indicate that c-kit is constitutively expressed on human osteoclasts and that it may be directly implicated in cell contact-dependent interaction of osteoclasts with other specialized or accessory cell populations of the bone microenvironment. Our observations suggest a role for SCF in human diseases characterized by abnormal bone resorption and remodeling.


This article has been cited by other articles:


Home page
BloodHome page
S. C. Derderian, P. P. Togarrati, C. King, P. W. Moradi, D. Reynaud, A. Czechowicz, I. L. Weissman, and T. C. MacKenzie
In utero depletion of fetal hematopoietic stem cells improves engraftment after neonatal transplantation in mice
Blood, August 7, 2014; 124(6): 973 - 980.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. Mansour, G. Abou-Ezzi, E. Sitnicka, S. E. W. Jacobsen, A. Wakkach, and C. Blin-Wakkach
Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow
J. Exp. Med., March 12, 2012; 209(3): 537 - 549.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, and A. C. W. Zannettino
Dysregulation of bone remodeling by imatinib mesylate
Blood, January 28, 2010; 115(4): 766 - 774.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
P. Spessotto, F. M. Rossi, M. Degan, R. Di Francia, R. Perris, A. Colombatti, and V. Gattei
Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9
J. Cell Biol., September 16, 2002; 158(6): 1133 - 1144.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Vitelli, G. Condorelli, V. Lulli, T. Hoang, L. Luchetti, C. M. Croce, and C. Peschle
A Pentamer Transcriptional Complex Including tal-1 and Retinoblastoma Protein Downmodulates c-kit Expression in Normal Erythroblasts
Mol. Cell. Biol., July 15, 2000; 20(14): 5330 - 5342.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Gattei, A. Celetti, A. Cerrato, M. Degan, A. De Iuliis, F. M. Rossi, G. Chiappetta, C. Consales, S. Improta, V. Zagonel, et al.
Expression of the RET Receptor Tyrosine Kinase and GDNFR-alpha in Normal and Leukemic Human Hematopoietic Cells and Stromal Cells of the Bone Marrow Microenvironment
Blood, April 15, 1997; 89(8): 2925 - 2937.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.